Okyo Pharma Share Discussion Threads

[7willt18] 29/7/2020 23:44

This will be going a lot higher in the coming months. News will be on its way. Simply sit and hold for holders, we will be looking at £’s

[albert arthur] 28/7/2020 11:07

Nice bounce.

Fully locked and loaded, great way to get round dilution, an overall value of worst case 5% dilution that if they took those as equity... Also interesting they can’t touch those until early 2021.. Something big is going on around then.

Also interesting we had no warrants exercised and also to 3% (TR1) selling after a 2000% gain.

This is a hot stock in my eyes.

[spurs90] 28/7/2020 10:06

OKYO Pharma Limited
("OKYO" or the "Company")

Issue of convertible loan notes to raise £3,500,000

OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it has raised £3,500,000 through the issue of convertible loan notes ("CLNs"). The proceeds of the CLNs will be used for working capital purposes as detailed below. The CLNs carry an interest rate of 2.15% compounding and have maximum term of 4 years. The CLNs convert into ordinary shares at a price of 8.5p per share. Conversion will be subject to shareholder approval and no conversions may take place prior to 28 February 2021.

The CLNs were placed with a small number of private investors.

OKYO intends to use the net proceeds received from the CLNs, to further the development of its clinical pipeline.

The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Chief Financial Officer of OKYO.

[volsung] 28/7/2020 09:01

Bought some more at 9.99p

[newtoaim] 27/7/2020 14:25

Over valued and risen on hot air and no news just pumps

[newtoaim] 27/7/2020 14:24

No more then

[volsung] 27/7/2020 11:02

A few mor at 11.1p

[terry508] 25/7/2020 19:25

You got a time machine then Spurs?

[spurs90] 25/7/2020 13:30

Lol!!!! Yes still here in case anyone missed it from a well respected investment journalist

Also talking of current shareholders, speculation in the market regarding StemPrintER being folded into Okyo is incorrect, something which may have been a distraction for observers of both entities.

GLA

I might buy some at 6p lol!!!

[terry508] 25/7/2020 10:14

Go for it, confirm your position once you done it

[jerseysteve] 25/7/2020 09:06

Time to short these shares now as they have said no deal with tils

[albert arthur] 24/7/2020 21:26

Iminent, slight COVID delay.

[p5tvr] 24/7/2020 20:13

Where are the full year results? last year's was on 01/07/19!!

[albert arthur] 24/7/2020 18:09

Don't blow anything out the water... I've researched this to the bone.

[albert arthur] 24/7/2020 18:09

Great week here !

[goldensharewolf] 24/7/2020 15:21

The only man stalking BB's not interested in making money ?#bitter

[goldensharewolf] 24/7/2020 15:19

?The only man on BB not interested in making money!

[spurs90] 24/7/2020 15:01

Not interested And couldn’t give a monkey just glad you people will stop posting utter drivel on boards you shouldn’t be posting on

[goldensharewolf] 24/7/2020 14:54

What was Zak's share price target Spurs?

[cumnor] 24/7/2020 14:02

Well, well, near 20 times jump in share price from placing price on no news that could remotely account for the rise-normally a company would come out with a 'we know no reason,,,,,' or 'if the directors have inside info relating to the rise it would of course, we presume, have been released if it is affecting the share price. But who knows?
Big connections here with TILs-are its shareholders in for a reward, or a surprise re StemPrinter? Looking forward to see how the demerger transpires. imo

[spurs90] 24/7/2020 05:22

IQ-AI Ltd

("IQ-AI" or the "Company")



Imaging Biometrics in Collaboration With Three Top Imaging Centers

Awarded $2.57m NIH Grant





Imaging Biometrics™, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI), in collaboration with the Barrow Neurological Institute (BNI), the Mayo Clinic (AZ), and the Medical College of Wisconsin (MCW), has received a $2.57 million, five-year grant award from the National Institutes of Health(NIH) - National Cancer Institute (NCI). Funding for this effort begins 1st July with the primary purpose of optimising and validating multi-vendor quantitative perfusion tools for the prediction of brain tumor response to therapy on a patient-specific basis.

Principal Investigator, Chad Quarles, PhD, Professor and Chair of the Division of Neuroimaging Research at BNI (Phoenix, AZ), will lead this multi-institutional effort to provide brain tumor physicians with a novel MRI method that provides several different measures of tumor biology using just one MRI technique, called SAGE (spin and gradient echo [MRI]). The additional biological information will help doctors determine how best to combine therapies, and will complement IB's current methods of monitoring treatment response. This NIH-funded effort also includes a plan to harmonise the way SAGE data is collected and analysed across sites and MRI vendors. IB's experience in providing vendor-neutral and standardised software is key to this effort, and IB's participation in this effort will further expand its footprint as the recognised leader in brain cancer imaging and assessing treatment response.


Michael Schmainda, CEO of IB, added, "Since our inception in 2007, NIH grant funding has helped fuel our business by enabling us to accelerate the development and translation of novel imaging technologies into practical products. Not only does this grant provide a financial boost for IB, it further strengthens our relationships with recognized leaders in MR imaging.